News Releases

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, and PHVS719 Phase 1 PK study expected to initiate in 2021 Executing from a strong

Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding HAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in 2021 Viviane Monges nominated to Board of Directors and as Chair of the Audit Committee Strong

Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients ZUG, Switzerland, May 12, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the

RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE Open IND for the prophylactic evaluation of PHVS416 Strong pre-IPO cash and cash equivalents balance of €98.6 million as of December 31, 2020 ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris

Company on track to initiate prophylactic study of PHVS416 ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema